Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Interferon Alfa
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study
Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for patients with Sjögren's syndrome.
Brand Name : Veldona
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 11, 2024
Lead Product(s) : Interferon Alfa
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ainos Plans Taiwan Study for VELDONA in HIV-Related Oral Warts
Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for oral warts in HIV-seropositive patients.
Brand Name : Veldona
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 17, 2024
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon Alfa
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $9.0 million
Deal Type : Financing
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
Details : The financing will be used to advance company's products including VELDONA (interferon alfa) which binds to type I interferon receptors (IFNAR). It is being evaluated for thrombocytopenia.
Brand Name : Veldona
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 07, 2024
Lead Product(s) : Interferon Alfa
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $9.0 million
Deal Type : Financing
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ainos Submits Clinical Hold Response to FDA for VELDONA Trial Against Mild COVID-19
Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated in phase 1 clinial trials for the treatment of mild COVID-19 symptoms.
Brand Name : Veldona
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 05, 2024
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon Alfa
Therapeutic Area : Hematology
Study Phase : IND Enabling
Sponsor : Lind Partners
Deal Size : $1.7 million
Deal Type : Financing
Ainos Announces $1.75 Million Follow-On Funding
Details : Veldona (interferon alfa) is progressing towards IND applications for human drug candidates and co-development of VOC sensing tech using AI Nose.
Brand Name : Veldona
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 24, 2024
Lead Product(s) : Interferon Alfa
Therapeutic Area : Hematology
Highest Development Status : IND Enabling
Sponsor : Lind Partners
Deal Size : $1.7 million
Deal Type : Financing
Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for oral warts in HIV-seropositive patients.
Brand Name : Veldona
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 21, 2023
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Veldona is a low-dose oral interferon formulation investigated as a potential treatment for oral warts in HIV-seropositive patients. Ainos plans to pursue a pre-IND meeting with the U.S. FDA in advance of planned Phase III clinical studies for the drug c...
Brand Name : Veldona
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 18, 2023
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon Alfa
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Merdury Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Ainos and Merdury will evaluate the feasibility of Merdury's potential investment and participation in the completion of a Phase 3 clinical trial of the Company's Veldona (interferon alfa) drug candidate for treatment of oral warts i...
Brand Name : Veldona
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 14, 2023
Lead Product(s) : Interferon Alfa
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Merdury Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Interferon Alfa
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Veldona, a low-dose oral interferon-alpha formulation to boost the human body’s frontline defenses against disease and infection. IFN-α is a key component of our body’s innate immune response to viral infection. Most cells in the body will produce i...
Brand Name : Veldona
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 31, 2022
Lead Product(s) : Interferon Alfa
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A pre-clinical animal study we conducted since March of this year validated the effectiveness of our low-dose oral Veldona (interferon) therapy to protect against COVID-19.
Brand Name : Veldona
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 24, 2022
Lead Product(s) : Interferon Alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?